After promising clinical trials, the Food and Drug Administration (FDA) has approved a drug called Saxenda for chronic weight management that will be available by prescription to overweight and obese adults.
Intended to accompany a diet and physical fitness program, Saxenda is a once-daily injection of an imitation of the hormone GLP-1 (glucagon-like peptide) that tells as their pharmicudical counterpart when the stomach is full.
The treatment is not with no risks, amongst which include pancreatitis, gall bladder disease, hypoglycemia and changes in spirits and behavior.
Side effects consist of upset stomach, fatigue, dizziness as well as abdominal pain, according to a corporation press release.
Saxenda joins Contrave, the same drug that won FDA approval in early September on this year.
Like Saxenda, Contrave should be used accompanied by a diet and exercise regime, although treatment contains two drugs called naltrexone HCl and bupropion HCl that band together to suppress hunger.
Also similar to Saxenda, the medication is not for all, and those interested should consult with their doctor about whether medication will be the appropriate way to address their weight excess.
Contrave is currently under review by the European Medicines Agency (EMA) intended for approval in Europe.